V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330004739 | 330002287 | 1.63 | 60 | Palliative (P) | 2015-03-14 | 2015-03-14 | Carboplatin + Doxorubicin | 02 | null | 330019971 | PEMBROLIZUMAB |
| 330004741 | 330002289 | 1.59 | 10.4 | Curative (C) | null | 2018-03-15 | METHOTREXATE | null | null | 330019978 | SUNITINIB |
| 330004742 | 330002290 | 0 | 103 | Palliative (P) | 2013-10-04 | 2013-10-09 | VIDE | 2 | N | 330019979 | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN |
| 330004743 | 330002291 | 1.64 | 67.8 | Curative (C) | null | 2015-03-27 | EP/EMA | N | N | 330019995 | BEVACIZUMAB |
| 330004744 | 330002291 | 1.85 | null | Adjuvant (A) | 2016-06-19 | 2016-07-10 | FLUOROURACIL + IRINOTECAN | null | N | 330019995 | CARBOPLATIN + VINCRISTINE |
| 330004745 | 330002292 | null | 48.6 | Palliative (P) | 2015-05-28 | 2015-06-01 | Hydroxycarbamide | Y | N | 330020004 | BLEOMYCIN + CARBOPLATIN + ETOPOSIDE |
| 330004747 | 330002294 | 1.5 | null | Curative (C) | 2014-04-14 | 2014-05-08 | FLAG + Idarubicin | N | N | 330020008 | CHLORAMBUCIL + RITUXIMAB |
| 330004748 | 330002295 | 1.59 | 58.1 | null | 2015-11-16 | 2015-11-23 | OCTREOTIDE | null | N | 330020010 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 330004752 | 330002296 | null | 19.7 | Palliative (P) | 2017-05-05 | 2017-05-06 | AML17 TRIAL | N | N | 330020028 | TEMOZOLOMIDE |
| 330004753 | 330002297 | 1.77 | 17.5 | Palliative (P) | 2017-07-16 | 2017-07-19 | BEP 5 Day | 02 | N | 330020032 | EPIRUBICIN |
| 330004754 | 330002298 | 1.74 | 24.4 | Palliative (P) | 2013-09-07 | 2013-09-19 | ACE (germ cell) | N | N | 330020033 | AML16 TRIAL |
| 330004755 | 330002299 | 1.63 | 72.3 | null | 2014-02-28 | 2014-03-02 | CARBOPLATIN + RT | N | N | 330020043 | ETOPOSIDE |
| 330004756 | 330002300 | null | 61.5 | Palliative (P) | 2015-11-17 | 2015-12-12 | Bevacizumab 5mg/kg | N | N | 330020045 | DOXORUBICIN + IFOSFAMIDE |
| 330004757 | 330002301 | 1.41 | 58 | null | 2015-07-12 | 2015-07-22 | Trastuzumab Subcutaneous | null | null | 330020049 | DOXORUBICIN + IFOSFAMIDE |
| 330004759 | 330002303 | null | 57 | Disease modification (D) | 2016-10-15 | 2016-10-20 | VAI (Ifos 3g/m2) | N | N | 330020060 | HYDROXYCARBAMIDE |
| 330004760 | 330002303 | 1.8 | 78 | Palliative (P) | 2015-12-26 | 2015-12-27 | CHOP R - 21 days | N | N | 330020060 | CYTARABINE |
| 330004761 | 330002303 | null | null | Disease modification (D) | 2017-06-30 | 2017-07-03 | CYCLOPHOSPHAMIDE + ETOPOSIDE + VINCRISTINE | Y | N | 330020060 | DOXORUBICIN + IFOSFAMIDE |
| 330004762 | 330002303 | 1.89 | 91.5 | Curative (C) | 2014-02-08 | 2014-02-11 | Bendamustine + prednisolone | 02 | Y | 330020060 | CYCLOPHOSPHAMIDE |
| 330004763 | 330002303 | 1.69 | null | Curative (C) | 2013-06-02 | 2013-06-08 | Cytarabine Low Dose | 02 | N | 330020060 | VINBLASTINE |
| 330004764 | 330002304 | 1.78 | 67 | Palliative (P) | 2015-03-01 | 2015-03-01 | CARBOPLATIN + RT | 2 | N | 330020076 | CYCLO + DOXORUBICIN + VINCRISTINE |
| 330004765 | 330002304 | 1.91 | 68.5 | Adjuvant (A) | 2013-06-08 | 2013-06-09 | Imatinib 400mg | N | N | 330020076 | RUXOLITINIB |
| 330004766 | 330002305 | 1.7 | 67 | Curative (C) | 2013-10-04 | 2013-10-04 | Hydroxycarbamide | 2 | N | 330020091 | DOCETAXEL |
| 330004767 | 330002305 | 1.7 | 77 | Neo-adjuvant (N) | 2017-08-20 | 2017-09-01 | AML Int Guide ADE 10+3+5 (1) | 02 | N | 330020091 | PACLITAXEL |
| 330004768 | 330002305 | null | 0 | Curative (C) | 2014-11-05 | 2014-11-11 | EMA/CO | N | N | 330020091 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330004769 | 330002306 | 1.85 | 71.6 | Palliative (P) | 2013-07-15 | 2013-07-16 | Cisplatin + Pemetrexed | 02 | N | 330020103 | BEP |
| 330004772 | 330002308 | 1.83 | 88 | Not known (9) | 2015-01-09 | 2015-01-25 | Azacitidine | N | N | 330020129 | VIDE |
| 330004773 | 330002308 | 1.81 | null | Neo-adjuvant (N) | 2016-08-31 | 2016-10-04 | ALL UKALL2011 Ind A Sht Dex (PAsp) | N | N | 330020129 | FLAG + IDARUBICIN |
| 330004774 | 330002308 | 1.77 | null | null | 2014-08-05 | 2014-08-11 | Paclitaxel 7 day | Y | N | 330020129 | RUXOLITINIB |
| 330004775 | 330002309 | 1.72 | 65.2 | Neo-adjuvant (N) | 2016-04-17 | 2016-04-26 | ETOPOSIDE + IFOSFAMIDE | 2 | N | 330020137 | EDP + MITOTANE |
| 330004776 | 330002309 | 0 | null | Palliative (P) | 2017-02-10 | 2017-02-12 | FLAG + Idarubicin | N | N | 330020137 | AML17 TRIAL |
| 330004777 | 330009944 | 1.67 | 0 | Palliative (P) | 2017-11-14 | 2017-12-04 | Docetaxel | 02 | N | 330020153 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL |
| 330004778 | 330009944 | 1.69 | 59.5 | null | 2016-04-06 | 2016-06-02 | Etoposide + Ifosfamide (3 days) | 02 | N | 330020153 | RMS 2005 TRIAL |
| 330004779 | 330009944 | 1.72 | 66 | Palliative (P) | 2017-01-29 | 2017-02-01 | BLEOMYCIN + CISPLATIN + VINCRISTINE | Y | N | 330020153 | CAPECITABINE + RT |
| 330004780 | 330009944 | 1.64 | 52.6 | Palliative (P) | 2013-02-17 | 2013-02-18 | DABRAFENIB | 02 | N | 330020153 | PAZOPANIB |
| 330004781 | 330012969 | 1.21 | 57.7 | Disease modification (D) | 2017-08-27 | 2017-09-05 | Ipilimumab | N | N | 330020176 | IMATINIB |
| 330004782 | 330002310 | 1.59 | 39.3 | Curative (C) | 2014-05-18 | 2014-05-20 | Imatinib 400mg | N | N | 330020179 | CARBOPLATIN + VINCRISTINE |
| 330004783 | 330002310 | 1.68 | 54.2 | Curative (C) | 2014-11-12 | 2014-11-26 | CAPECITABINE + GEMCITABINE | N | N | 330020179 | FLAG |
| 330004784 | 330002310 | 1.48 | 88 | Palliative (P) | 2013-10-24 | 2013-10-24 | Bortezomib +/- Dexamethasone | N | N | 330020179 | MERCAPTOPURINE |
| 330004785 | 330002310 | 1.6 | 76.4 | Palliative (P) | 2014-03-09 | 2014-03-22 | Etoposide + Ifosfamide (3 days) | N | N | 330020179 | VIDE |
| 330004786 | 330002310 | 0 | 61 | Palliative (P) | 2013-12-02 | 2013-12-10 | Doxorubicin + Ifosfamide | Y | N | 330020179 | HYDROXYCARBAMIDE |
| 330004790 | 330002312 | 1.53 | 98 | Curative (C) | 2015-07-19 | 2015-08-30 | DOXORUBICIN + IFOSFAMIDE | N | N | 330020208 | CAV |
| 330004791 | 330002313 | 1.75 | null | Curative (C) | 2016-04-17 | 2016-04-20 | ALL UKALL2011 Ind A Sht Dex (PAsp) | N | N | 330020209 | IPILIMUMAB + NIVOLUMAB |
| 330004792 | 330002313 | null | 69.7 | Curative (C) | 2014-02-02 | 2014-02-02 | Bevacizumab 5mg/kg | 02 | N | 330020209 | DACARBAZINE |
| 330004793 | 330002314 | null | null | Palliative (P) | 2017-12-14 | 2018-01-02 | BEP 5 Day | null | null | 330020214 | FCR |
| 330004794 | 330002315 | 1.57 | 74.35 | Disease modification (D) | 2014-08-15 | 2014-09-18 | Methotrexate intrathecal | N | N | 330020223 | AML17 TRIAL |
| 330004798 | 330002317 | 1.68 | 59.7 | Palliative (P) | 2015-05-23 | 2015-05-24 | CARBOPLATIN + CETUXIMAB + FU | 2 | N | 330020243 | IMATINIB |
| 330004800 | 330009948 | 1.67 | 56.7 | Curative (C) | 2013-07-15 | 2013-07-15 | Cisplatin + Pemetrexed | Y | N | 330020252 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330004801 | 330002318 | 1.8 | 64.3 | Palliative (P) | 2015-03-04 | 2015-03-04 | Cetuximab +Cisplatin + FU (Cycle 1) | 02 | N | 330020254 | UKALL2014 |
| 330004802 | 330007276 | 1.75 | 67 | Curative (C) | 2014-12-08 | 2014-12-10 | ALL UKALL2011 Ind A Std Dex (PAsp) | Y | N | 330020257 | CHOP R |
| 330004803 | 330002319 | null | null | Disease modification (D) | 2013-06-08 | 2013-06-15 | AFLIBERCEPT + FU + IRINOTECAN | null | null | 330020260 | BLEOMYCIN + CISPLATIN + VINCRISTINE |